[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontal-disease":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,44,73,108,139,164,192,214,236,260,288,319,355,373,399,422,445,468,497,529,554,581,604,625,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100652161","effect-of-glp-1-receptor-agonists-on-periodontal-health-and-response-to-nonsurgical-periodontal-therapy-100652161",false,"NCT07770906","Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy","Effect of Glucagon-Like Peptide-1 Receptor Agonist Use on Periodontal Health and Response to Non-Surgical Periodontal Therapy","GLP1-PERIO","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Body mass index (BMI) ≥25 kg\u002Fm²\n* Presence of at least 20 functional teeth\n* Diagnosis of periodontitis\n* For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months\n\nExclusion Criteria:\n\n* Age between 18 and 65 years\n* Body mass index (BMI) ≥25 kg\u002Fm²\n* Presence of at least 20 functional teeth\n* Diagnosis of periodontitis\n* For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months","ALL",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.\n\nParticipants with obesity and periodontitis will be divided into two groups: those who have been using a GLP-1 RA for at least 3 months and those who are not using any medication for obesity. All participants will receive the same non-surgical periodontal treatment, including oral hygiene instruction, scaling, and root planing.\n\nPeriodontal clinical measurements and gingival crevicular fluid samples will be collected before treatment and at 3 and 6 months after treatment. The study will compare changes in periodontal health and inflammatory markers between the two groups to determine whether GLP-1 RA use is associated with periodontal health and the response to non-surgical periodontal therapy.",[27,28],"Periodontal Disease","Obesity & Overweight",[30,31],"PERIODONTAL DISEASE","OBESİTY","NOT_YET_RECRUITING","2026-08-18",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":21},"2026-09-01",{"date":40,"type":21},"2027-12-01",{"name":42,"class":43},"Cukurova University","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100621955","cheer-oral-health-in-pregnancy-study-100621955","NCT07377344","CHEER Oral Health in Pregnancy Study","Closing Health Equity Through Empowering Oral Health for Maternal Wellness","CHEER","Inclusion Criteria:\n\n1. Pregnant individuals aged 18 years or older with indications of periodontal diseases (gingivitis or mild periodontitis, moderate to severe periodontitis)\n2. Less than 20 weeks pregnancy at time of enrollment\n3. Has dental insurance (Medi-Cal or private coverage)\n4. Willing and able to provide informed consent\n5. Planning to receive ongoing prenatal care at study-affiliated clinics\n6. Access to a mobile phone for receiving text messages\n\nExclusion Criteria:\n\n1. Presence of systemic diseases or medical conditions that require antibiotic prophylaxis for dental procedures\n2. Current immunosuppressive therapy\u002Fuse of anti-inflammatory medications\n3. Receipt of active periodontal treatment within the past 6 months\n4. Complete edentulism (no natural teeth)\n5. Unable to read and write English\n6. Less than 9th grade education\n7. Enrollment in another oral interventional study","FEMALE","18 Years",{"count":55,"type":21},160,[24],"Many pregnant people don't get the dental care they need, even though it's safe and important. The CHEER Study offers free dental check-ups, cleanings, and supplies to help participants take care of their teeth and gums during pregnancy. The purpose of this research study is to compare two types of noninvasive oral health interventions to evaluate their effectiveness. We want to learn if one method is more effective in supporting oral health and improving pregnancy outcomes. There are two aims of this study:\n\nAim 1: To evaluate whether a structured oral health intervention reduces periodontal inflammation during pregnancy and postpartum in pregnant people with indicators of periodontal disease.\n\nAim 2: To assess whether a structured oral health intervention is associated with changes in oral health behaviors or birth outcomes in pregnant people with periodontal disease.",[59,60,61,62,63,27,64],"Gingivitis","Dental Health","Pregnancy","Pregnancy Outcomes","Randomized Controlled Trial","Gum Disease",{"date":35,"type":36},{"date":67,"type":21},"2026-09-30",{"date":69,"type":21},"2028-12-31",{"name":71,"class":43},"University of California, San Francisco",1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":4,"leadSponsor":105,"locationsCount":72},"100176270","oral-bacteria-and-immune-system-problems-involved-in-gum-disease-periodontitis-100176270","NCT01568697","Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)","Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction","* INCLUSION CRITERIA:\n\nSubjects with Genetic Immune Defects:\n\nPatients with a known genetic immune defect will be eligible for screening inclusion under this protocol.\n\n* Diagnosed with a genetic immune defect\n* Willing to allow genetic testing\n\n  * 7 years old\n\nSubjects with Severe Periodontitis of Suspected Genetic Etiology:\n\n* History of severe periodontitis prior to age \\\u003C30\n* Willing to allow genetic testing\n\n  -\\>=7 years old\n* In good general health\n\nFamily members of Subjects with Severe Periodontitis of Suspected Genetic Etiology:\n\n-Willing to allow genetic testing\n\n-\\>=7 years old\n\nHealthy Volunteer Subjects (with\u002Fwithout periodontitis):\n\n* In good general health\n\n  -\\>=18 years old\n* Willing to allow genetic testing\n* Have a minimum of 20 natural teeth\n\nInclusion Criteria for Natural History phase, all subjects:\n\n* Diagnosis of genetic immune defect\n* Presence of oral manifestation (primarily periodontitis)\n\nCriteria for standard of care treatment:\n\n* Active untreated disease (visible signs of tissue inflammation including erythema\u002Fedema, generalized bleeding upon probing)\n* Periodontal disease defined as bone loss of \\>=5mm as measured on periodontal exam.\n\nEXCLUSION CRITERIA:\n\nAll Subjects:\n\n* History of Hepatitis B or C\n* History of HIV\n* Prior radiation therapy to the head or neck\n* Have an active malignancy except localized basal or squamous cell carcinoma of the skin\n* Have been treated with systemic chemotherapeutics or radiation therapy within 5 years of screening\n* Pregnant or lactating\n* If participation in the protocol would not be safe or in the subject s best interest in the opinion of either the PI or the primary medical team.\n\nAdditional Exclusions for Healthy Volunteers:\n\n* Diagnosis of diabetes and\u002For HbA1C level \\>6%\n* More than 3 hospitalizations in the last 3years\n* Have an autoimmune disorder such as Lupus, Rheumatoid arthritis, etc.\n* In the 3 months before study enrollment, have used any of the following:\n\n  * Systemic (intravenous, intramuscular, or oral) antibiotics\n  * Oral, intravenous, intramuscular, intranasal, or inhaled corticosteroids or other immunosuppressants (e.g., cyclosporine)\n  * Cytokine therapy\n  * Methotrexate or immunosuppressive chemotherapeutic agents\n  * Large doses of commercial probiotics (\\>=10\\^8 colony-forming units or organisms per day); includes tablets, capsules, lozenges, chewing gum, or powders in which a probiotic is a primary component; ordinary dietary components such as fermented beverages\u002Fmilks, yogurts, and foods do not apply\n* Have used tobacco products (including e-cigarettes) within 1 year of screening\n* Unwillingness to consent to oral biopsy\n* NIH employees working in the Oral Immunity and Inflammation Unit and members of the Clinical Research Core Team will not be eligible for enrollment.\n\nAdditional Exclusions for Standard of Care Treatment at NIH:\n\n* Mild\u002Fmoderate non-active disease (absence of active inflammatory lesions)\n* Subjects with urgent\u002Fcomplex restorative needs (ex. severe active carious lesions\u002Ffractured dentition)\n* Subjects in need for advanced prosthetic needs (including implants and restorations)",true,"7 Years","100 Years",{"count":84,"type":21},700,"OBSERVATIONAL","Background:\n\n\\- Gum disease is a condition in which the tissue around the tooth root becomes swollen and infected. This condition can cause tooth loss if it is not treated. Who gets gum disease and how bad it will be depends on (1) the different bacteria in the mouth and (2) how the immune system of an individual handles these bacteria. Researchers want to look at the oral bacteria and genetic immune problems of different people to learn how these affect gum disease and other conditions of the mouth.\n\nObjectives:\n\n\\- To study how immune system problems may lead to problems in the mouth, including gum disease.\n\nEligibility:\n\n* Children and adults at least 7 years of age who have genetic problems with their immune system.\n* Healthy adults that have periodontal disease\n* Health adults that do not have periodontal disease\n\nDesign:\n\n* This study will involve a screening visit and a study visit.\n* Participants will be screened with a medical history, blood work and a full oral and dental exam, including dental x-rays and photos.\n* The study visit will involve collection of blood, urine, and other samples, including saliva, plaque, and gum swabs. Any abnormal tissue will sampled for a biopsy. Additional oral and dental exams will be performed. Participants will also answer questions about any current medical or dental problems.",[88,27,89,90],"Immunosuppression","Healthy Subjects","Healthy Volunteer",[92,93,94,95,96,97,27,64,90,98],"Microbiome","Periodontitis","Oral Mucosal Immunity","Oral Infection","Natural History","Immune Disorder","HV","RECRUITING","2026-08-05",{"date":102,"type":36},"2026-08-06",{"date":104,"type":36},"2012-10-05",{"name":106,"class":107},"National Institute of Dental and Craniofacial Research (NIDCR)","NIH",{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":80,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":85,"phases":4,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":72},"100650201","discovery-and-validation-of-biomarkers-for-periodontitis-dental-caries-and-oral-squamous-cell-carcinoma-100650201","NCT07745803","Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell Carcinoma","Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell Carcinoma: A Multi-Disease Cohort Study","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Adults aged 18 years or older.\n2. Able to understand the study information and provide written informed consent.\n3. Meet the criteria for one of the study groups based on clinical evaluation and disease assessment, including:\n\nOral squamous cell carcinoma (OSCC); Periodontal disease; Dental caries; Oral health without the corresponding diseases (healthy controls).\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Edentulous individuals.\n2. History of radiotherapy to the head and neck region.\n3. Presence of immunodeficiency conditions (for example, human immunodeficiency virus infection).\n4. Pregnancy.",{"count":116,"type":21},4000,"4 Years","The goal of this observational study is to develop better ways to detect and predict major oral diseases, including oral cancer, gum disease, and tooth decay. This study will collect detailed oral health information and biological samples from adults with different oral health conditions and healthy participants to identify markers that may help doctors detect diseases earlier and predict how diseases may change over time. The main questions this study aims to answer are whether biological markers from saliva, mouth rinse samples, blood, or oral tissue samples can help identify people with oral diseases, whether these markers can predict future disease changes such as worsening gum disease, new or progressing tooth decay, or recurrence and spread of oral cancer, and whether combining clinical information with biological markers can improve disease detection and risk prediction. Participants will receive a standard oral health examination, provide information about their health history and oral health behaviors, provide biological samples when appropriate, and be followed over time through clinical visits, questionnaires, and health information collection. Researchers will compare findings among people with different oral health conditions and healthy participants to better understand disease-related changes and develop tools for earlier detection and prediction of oral disease outcomes.",[120,27,121],"Oral Squamous Cell Carcinoma (OSCC)","Dental Caries",[123,124,125,126,127,128,129],"Oral disease","Oral squamous cell carcinoma","Periodontal disease","Dental caries","Biomarkers","Early detection","Prognostic prediction","2026-08-03",{"date":132,"type":36},"2026-08-04",{"date":134,"type":21},"2026-08-25",{"date":136,"type":21},"2031-12-30",{"name":138,"class":43},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":18,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100649534","phase-1-evaluation-of-nipsa-using-alloplastic-bone-graft-and-cross-linked-hyaluronic-acid-in-thetreatment-of-intrabony-defects-100649534","NCT07737678","Evaluation of NIPSA Using Alloplastic Bone Graft and Cross-Linked Hyaluronic Acid in theTreatment of Intrabony Defects","Evaluation of Non-Incised Papillae Surgical Approach Using Alloplastic Bone Graft and Cross-Linked Hyaluronic Acid in the Treatment of Intrabony Defects (A Randomized Controlled Clinical Trial)","RCT","Inclusion Criteria:\n\n1. Age range: 35 to 65 years old.\n2. Patients diagnosed with stage III. Periodontitis\n3. Presence of isolated intrabony defect with PPD ≥ 6 mm, CAL ≥ 6 mm\n4. Intrabony defect depth ≥3 mm.\n5. Contained an intrabony defect, 3-wall intrabony defect.\n6. No periodontal treatment has been administered in the previous six months.\n7. Full-mouth plaque score ≤ 10%.\n8. Full-mouth bleeding score ≤ 10%. -\n\nExclusion Criteria:\n\n1. Smokers ≥ 10 cigarettes per day\n2. Patient with systemic disease.\n3. Pregnant or lactating patients.\n4. Patient who has traumatic occlusion.\n5. Noncompliant patient.\n6. Patient with multi-rooted teeth with class II \\& III furcation involvement.","35 Years","65 Years",{"count":150,"type":21},60,[152,153],"PHASE1","PHASE2","Sixty patients will be selected from the outpatient clinic in the Oral Medicine and Periodontology Department, Faculty of Dentistry, Mansoura University, Egypt, according to preoperative clinical and radiographic data that will be used to evaluate the bone destruction pattern.",[156,27],"Intrabony Periodontal Defect","2026-08-01",{"date":132,"type":36},{"date":157,"type":21},{"date":161,"type":21},"2027-03-01",{"name":163,"class":43},"Mansoura University",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":80,"sex":52,"minAge":53,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100645814","maternal-periodontal-inflammation-and-pregnancy-outcomes-salivary-and-amniotic-biomarkers-100645814","NCT07699978","Maternal Periodontal Inflammation and Pregnancy Outcomes: Salivary and Amniotic Biomarkers","The Relationship Between Maternal Periodontal Inflammation and Pregnancy Outcomes: Evaluation Using Inflammatory and Oxidative Stress Biomarkers in Saliva and Amniotic Fluid","Inclusion Criteria:\n\n* Pregnant women between 28 and 32 weeks of gestation\n* Age 18 to 40 years\n* Singleton pregnancy\n* Systemically healthy\n* Normal gestational diabetes screening (oral glucose tolerance test within the hospital reference range)\n* Receiving only routine prenatal vitamin and iron supplementation (no therapeutic medications)\n* Low-risk pregnancy\n* No history of chorioamnionitis\n* No periodontal treatment within the previous 6 months\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Use of antibiotics or anti-inflammatory medications during pregnancy\n* Current smoking or alcohol consumption\n* Presence of an acute infection\n* Placental pathology\n* Major fetal anomaly\n* High-risk pregnancy as determined by the obstetrician\n* Refusal or inability to provide informed consent","40 Years",{"count":173,"type":21},80,"Periodontal disease is a chronic inflammatory condition that affects the tissues supporting the teeth and may contribute to systemic inflammation and oxidative stress. Increasing evidence suggests that maternal inflammation during pregnancy may be associated with adverse pregnancy outcomes, including preterm birth. However, the biological mechanisms linking maternal periodontal inflammation to the intrauterine environment remain unclear.\n\nThis prospective observational cohort study aims to investigate the relationship between maternal periodontal status and inflammatory and oxidative stress biomarkers measured in both saliva and amniotic fluid. Eighty healthy pregnant women between 28 and 32 weeks of gestation will be recruited from the Obstetrics and Gynecology Clinic of Gulhane Training and Research Hospital. Participants will undergo a comprehensive periodontal examination and provide unstimulated saliva samples. Amniotic fluid samples will be collected during delivery as part of routine obstetric care, without any additional invasive procedures.\n\nThe concentrations of 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), interleukin-6 (IL-6), and matrix metalloproteinase-8 (MMP-8) will be measured in saliva and amniotic fluid using enzyme-linked immunosorbent assay (ELISA). Pregnancy outcomes, including gestational age at delivery, birth weight, and pregnancy complications, will also be recorded.\n\nThe study will evaluate whether maternal periodontal inflammation is associated with changes in inflammatory and oxidative stress biomarkers in saliva and amniotic fluid and whether these biomarkers are related to pregnancy outcomes. The findings may improve understanding of the biological relationship between oral health and pregnancy and may contribute to the identification of biomarkers associated with adverse pregnancy outcomes.",[27,61,176],"Preterm Birth",[93,61,176,178,179,180,181,182,183],"Oxidative Stress","Inflammation","Saliva","Amniotic Fluid","8-Hydroxy-2'-deoxyguanosine (8-OHdG)","Interleukin-6 (IL-6)","2026-07-28",{"date":186,"type":36},"2026-07-29",{"date":35,"type":21},{"date":189,"type":21},"2027-08-15",{"name":191,"class":43},"Saglik Bilimleri Universitesi",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":72},"100628998","serum-inflammatory-protein-concentration-during-dental-treatment-100628998","NCT07468929","Serum Inflammatory Protein Concentration During Dental Treatment","Systemic Molecular Markers of Surgical Trauma in Periodontitis\u002FPeri-implantitis Patients","Inclusion Criteria:\n\n* Adults 21-75 years of age\n* Systemically healthy\n* Non-smoker\n* scheduled to receive nonsurgical or surgical periodontal treatment under IV sedation\n\nExclusion Criteria:\n\n* Patients who have localized form of the disease (less than 30% of available tooth\u002Fimplant sites are affected with the disease)\n* Non-english speaking individuals since informed consent form will be in English only.\n* Patients with uncontrolled systemic diseases (such as metabolic diseases, obesity, diabetes, high blood pressure) since these types of chronic inflammatory challenges would cause increase levels of circulatory serum pro-inflammatory markers.\n* Pregnant patients (pregnancy will be reported by the patient) since pregnancy itself would affect circulatory serum pro-inflammatory markers.\n* Patients who are not willing to have blood drawing for the study purpose.\n* Patients who are not willing to sign research related consent form.","21 Years","75 Years",{"count":202,"type":21},30,"The goal of this observational study is to study the molecular markers of stress in blood samples from people who are having periodontal surgery. The main question it aims to answer are:\n\n* How do the levels of inflammatory molecules in the blood change during a periodontal surgery?\n* How are the levels of inflammatory molecules in a person having surgery different from the levels in a person having a nonsurgical procedure?\n* Participants will be people who are having a periodontal surgery or a nonsurgical periodontal treatment as part of their dental care. Participants will be asked to let the investigator take blood samples from them before, during, and after the procedure is being done. The blood will later be analyzed for substances in the blood that are associated with inflammation.",[27,205],"Periodontal Surgery","2026-07-25",{"date":184,"type":36},{"date":209,"type":21},"2026-07",{"date":211,"type":21},"2027-02",{"name":213,"class":43},"Ohio State University",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":80,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":235},"100648668","thermosensitive-hyaluronic-gel-with-octenidine-as-an-adjunctive-to-subgingival-instrumentation-spontaneous-postmarketing-trial-with-a-medical-device-md-split-mouth-nationwide-multicenter-study-single-blind-randomized-controlled-trial-100648668","NCT07725913","Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation. Spontaneous, Postmarketing Trial With a Medical Device (MD), Split-mouth, Nationwide Multicenter Study Single-blind Randomized Controlled Trial","Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation: a Multicenter Randomized Clinical Study","PX-2025","Inclusion Criteria:\n\n* Patients agreeing to participate in the study\n* Age 18 years or older\n* ≥ 20 existing teeth (wisdom teeth excluded).\n* Diagnosis of periodontitis stage II-III or IV (any grade) of periodontitis\n* Each participant should have 2 or more contralateral quadrants with a minimum of 4 qualifying pockets of ≥ 5 mm that bled on probing\n* Full-mouth parallel periapical X-rays demonstrating bone loss (standard of care)\n\nExclusion Criteria:\n\n* • Pregnancy (confirmed, suspected, or uncertain), breastfeeding, or intention to become pregnant during the study period\n\n  * No antibiotic and periodontal therapy within the last 6 months\n  * Heavy smoking (more than 10 cigarettes\u002Fday)\n  * Chronic diseases such as uncontrolled diabetes mellitus (HbA1c ≥ 7.0%) or rheumatoid arthritis\n  * History of radiotherapy or chemotherapy\n  * Mucosal immune diseases\n  * Mental disorders\n  * Parafunctional habits such as bruxism\n  * Subjects with removable partial dentures\n  * Patients undergoing orthodontic therapy\n  * Sites next to recent extraction sockets\n  * Teeth showing endodontic-periodontic lesions\n  * Systemically healthy and no known allergies\n  * Subjects with a known hypersensitivity to hyaluronic acid or to any of the ingredients contained in the product formulation.",{"count":20,"type":21},[24],"This will be a spontaneous, postmarketing trial with a medical device (MD), split-mouth, nationwide multicenter study (coordinator center: Periodontal Unit, Dental Clinic, DIBINEM, Bologna University, Italy, with satellite center involved), single-blind (examiner), randomized controlled trial comparing, at different time points, the clinical efficacy of PX-Gel-a thermosensitive hyaluronic acid-octenidine gel-in enhancing gingival healing of periodontal pockets when used as an adjunct to scaling and root planing (test group) versus conventional SRP (control group). SRP represents the gold standard for non-surgical treatment of periodontitis and it is the standard of care.\n\nEach patient will contribute with at least 4 sites with a PD more than 5 mm and positive BOP in 2 contralateral quadrants. The sites will be randomly assigned to one of the two treatment regimens, using a predetermined computer- generated randomization scheme, regarding left or right side) to receive the test treatment (SRP + PX-gel) or to serve as SRP controls.\n\nAllocation concealment will be performed by opaque sealed envelopes, sequentially numbered. The allocation sequence will be generated by means of a computer-generated random list (https :\u002F\u002Fwww.sealedenve lope.com\u002Fsimple-randomiser\u002F v1\u002F) and a different subject (not involved in the treatment) will be instructed to assign a sealed envelope containing the treatments of each site (SRP+ PX-Gel or SRP). The opaque sealed envelope will be opened immediately after the end of the SRP session.\n\nBlinding of independent examiner will be maintained through-out all study period.\n\nThe patients will not be informed of the locations where the treatment gel will be applied.\n\nAll adult subjects referred to the Periodontal Unit and involved satellite center for periodontal treatment will be screened and enrolled in the study according to the following inclusion\u002Fexclusion criteria:\n\n* Patients agreeing to participate in the study\n* Age 18 years or older\n* ≥ 20 existing teeth (wisdom teeth excluded).\n* Diagnosis of periodontitis stage II-III or IV (any grade) of periodontitis\n* Each participant should have 2 or more contralateral quadrants with a minimum of 4 qualifying pockets of ≥ 5 mm that bled on probing\n* Full-mouth parallel periapical X-rays demonstrating bone loss (standard of care)",[27],"2026-07-21",{"date":228,"type":36},"2026-07-24",{"date":230,"type":36},"2026-02-01",{"date":232,"type":21},"2028-02-01",{"name":234,"class":43},"University of Bologna",2,{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":244,"maxAge":148,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100648027","probiotic-response-in-periodontal-disease-100648027","NCT07718074","Probiotic Response in Periodontal Disease","MicroPerio: Microbiome and Dietary Predictors of Probiotic Response in Periodontal Disease","MicroPerio","Inclusion Criteria:\n\n1. Age between 45 and 65 years: Restricting eligibility to this age range reduces potential confounding from age-related comorbidities and ensures adequate natural dentition for standardized gingival crevicular fluid (GCF) sampling.\n2. Diagnosis of Stage III periodontal disease (PD): Participants must have clinically confirmed Stage III (severe) PD according to the 2017 American Academy of Periodontology\u002FEuropean Federation of Periodontology (AAP\u002FEFP) classification system to ensure consistent disease severity among enrolled participants.\n\nExclusion Criteria:\n\n1. Use of prebiotic, probiotic, or fiber supplements within the previous 6 months: Recent use of microbiome-modulating supplements could alter baseline oral or gut microbial composition and confound assessment of responsiveness to the probiotic intervention.\n2. Use of antibiotics within the previous 6 months: Antibiotic exposure can cause sustained disruptions to host microbiomes and immune responses, which may confound evaluation of probiotic-related changes in inflammatory and microbial outcomes.\n3. Systemic diseases affecting the periodontium (uncontrolled diabetes mellitus defined as HbA1c ≥8%, autoimmune diseases): These conditions may independently influence periodontal inflammation, immune responses, and microbiome composition, potentially confounding interpretation of study outcomes.\n4. History of communicable or chronic diseases that may render study participation unsafe: Certain medical conditions may increase the risk of adverse events associated with study procedures or probiotic exposure.\n5. Pregnancy or breastfeeding: Physiological changes during pregnancy and lactation may influence periodontal status, immune function, and microbiome composition.\n6. Having fewer than 20 natural teeth: Adequate natural dentition is required to support standardized periodontal assessments and reliable biospecimen collection.\n7. Use of removable dentures: Denture use alters the oral microbiome and local inflammatory environment and may compromise the validity of periodontal outcome measures.\n8. Surgical periodontal disease treatment within the previous 6 months: Recent surgical intervention may induce substantial changes in the periodontal environment, complicating baseline measurement and interpretation of treatment response.\n9. Ongoing participation in another clinical trial: Concurrent participation in another trial may introduce overlapping interventions or behavioral changes that could compromise internal validity.\n10. Lack of mobility or physical independence: Physical limitations may make participation burdensome or interfere with attendance at study visits and completion of study procedures.\n11. Inability to communicate orally or in written English: Because study procedures and consent materials will be conducted in English, adequate language proficiency is required to ensure participants understand study instructions and provide informed consent.","45 Years",{"count":246,"type":21},100,[24],"Probiotics are live microorganisms that can be taken as supplements and have shown promise in playing a beneficial role in improving clinical conditions that are characterized by chronic inflammation, such as periodontal disease (PD). The human gut microbiome is composed of trillions of bacteria that reside throughout the gastrointestinal tract and has an important role in the modulation of inflammatory responses in the human host. There is evidence that PD is associated with alterations in the oral and gut microbiomes, suggesting that probiotics may reduce inflammation through microbiome modulation. However, individual responses to probiotics can be highly variable, and robust predictors of probiotic responsiveness remain poorly defined. There is also limited knowledge about how the oral and gut microbiome interact even though there is growing evidence for a bidirectional oral-gut axis with implications for host immunity, inflammation, and probiotic responsiveness. The overarching goal of this project is to identify oral and gut microbiome features that predict responsiveness to probiotic interventions as an adjuvant treatment for PD. We will conduct a double-blind randomized controlled trial in which New Hampshire adults with stage III PD will be randomized to receive a 12-week adjuvant intervention of either a daily probiotic (n=45) or placebo (n=45) lozenge. The probiotic intervention will consist of a once daily lozenge containing a standard dose of 200 million CFU of two strains of Limosilactobacillus reuteri (DSM 17938 and ATCC PTA 5289), a commercial formulation demonstrated to be safe and well-tolerated in this population over this treatment length. The primary outcome to quantify responsiveness to the probiotic as an adjuvant therapeutic for PD will be within-subject change from baseline in inflammatory markers, and oral and gut microbiome composition.",[27],[125,251,92],"Probiotic","2026-07-16",{"date":226,"type":36},{"date":255,"type":21},"2026-10",{"date":257,"type":21},"2028-07",{"name":259,"class":43},"University of New Hampshire",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":80,"sex":18,"minAge":267,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":72},"100647743","association-between-periodontal-disease-and-chronic-neck-pain-100647743","NCT07711431","Association Between Periodontal Disease and Chronic Neck Pain","Evaluation of the Association Between Periodontal Diseases and Chronic Non-Specific Neck Pain and Functional Disability: A Cross-Sectional Study","Inclusion Criteria:\n\n* Aged between 30 and 55 years\n* Willing to participate and provide written informed consent\n* Able to undergo periodontal examination and complete self-report questionnaires\n\nExclusion Criteria:\n\n* Neck pain attributable to a specific identifiable cause (e.g., trauma, cervical disc herniation, spinal deformity, tumor, fracture)\n* Systemic inflammatory or autoimmune disease\n* Neurological disease affecting the cervical region\n* Pregnancy\n* Regular use of analgesic or anti-inflammatory medication\n* Fewer than 20 remaining natural teeth\n* History of periodontal treatment within the past 6 months","30 Years","55 Years",{"count":270,"type":21},123,"This study investigates whether there is an association between periodontal disease (gum disease) and chronic neck pain and related functional disability. Participants aged 30-55 years will be grouped based on their periodontal health status (healthy, gingivitis, or periodontitis). Neck pain intensity will be assessed using the Visual Analog Scale (VAS), and functional disability will be measured using the Neck Disability Index (NDI). The study aims to determine whether periodontal disease severity is linked to the severity of neck pain and disability, which may help clarify a potential connection between oral health and musculoskeletal health.",[27,273],"Chronic Neck Pain",[27,59,93,275,276,277,278],"Neck Pain","Neck Disability","Oral Health","Musculoskeletal Pain","2026-07-14",{"date":281,"type":36},"2026-07-17",{"date":283,"type":36},"2026-07-11",{"date":285,"type":21},"2026-09-15",{"name":287,"class":43},"Nigde Omer Halisdemir University",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":299,"conditions":300,"keywords":303,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":72},"100647362","phase-4-this-a-clinical-trial-to-evaluate-the-efficacy-of-i-prf-povidone-iodine-and-laser-as-adjuncts-to-non-surgical-periodontal-treatment-in-smokers-and-non-smokers-periodontitis-patients-100647362","NCT07707063","This a Clinical Trial to Evaluate the Efficacy of I-PRF, Povidone-Iodine and Laser as Adjuncts to Non-surgical Periodontal Treatment in Smokers and Non-Smokers Periodontitis Patients","Clinical Efficacy of I-PRF, Povidone-Iodine and Laser as Adjuncts to Non-surgical Periodontal Treatment in Smokers and Non-Smokers Periodontitis Patients : A Split Mouth Randomized Clinical Trial","Inclusion: Patients with Stage II-IV Periodontitis; at least one bleeding pocket \\> 4 mm minimum in every quadrant.\n\nExclusion: patients who:\n\n* Pregnant \u002FLactating\n* History of radiotherapy or chemotherapy in the head\u002Fneck region.\n* Known hypersensitivity to Iodine or Methylene blue solution\n* Systematic antibiotic use within the last 30 days\n* Long-term use of immunosuppressants or corticosteroids (daily use)\n* type 1 \u002F 2 diabetes",{"count":296,"type":21},50,[298],"PHASE4","This study is a randomized, controlled, split-mouth clinical trial designed to evaluate and compare the effectiveness of four different subgingival adjuncts used along side standard Scaling and Root Planning (SRP). This protocol is designed to be a standardized therapeutic model. The subgingival adjuncts are standardized, ensuring that the results are not operator dependent and can be replicated across any dental unit. The primary goal of this study is to evaluate the clinical efficacy of three distinct adjunctive strategies: Biological (I-PRF), Antiseptic : Povidone- iodine , Diode-Laser activation, compared to a Saline Control in the initial treatment of stage 2, 3 and stage 4 of the 2018 AAP\u002FEFP periodontal classification.",[93,301,302,27],"Smokers","Non Smokers",[304,305,306,307,308,309,310],"Injectable platelet-rich fibrin (I-PRF)","Diode Laser","iodine solution","Periodontal Pockets","periodontal debridement","lasers","Regenerative periodontal therapy","2026-07-10",{"date":252,"type":36},{"date":314,"type":36},"2026-05-25",{"date":316,"type":21},"2027-05-18",{"name":318,"class":43},"Military Hospital of Tunis",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":80,"sex":52,"minAge":326,"maxAge":147,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":331,"conditions":332,"keywords":336,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":4},"100635484","phase-3-periodontal-disease-and-small-vulnerable-newborns-in-rural-nepal-a-community-based-trial-100635484","NCT07553286","Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Trial","Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Randomized Trial","Inclusion Criteria:\n\n* Married women of reproductive age (15-35 years).\n* Living in the study area who are pregnant and consent to participate.\n\nExclusion Criteria:\n\n* Currently pregnant women.\n* Women who are sterilized or use long-acting contraceptive methods or are divorced or widowed.\n* Women identified as pregnant ≥12 gestational weeks based upon date of last menstrual period.","15 Years",{"count":328,"type":21},2280,[330],"PHASE3","Periodontal disease in pregnant women has been implicated as a potential risk factor for adverse pregnancy outcomes, including being born preterm, small-for-gestational age, and\u002For low birth weight. Infants who have at least one of these outcomes, known as small vulnerable newborns (SVN)), are at increased risk of early death and poor infant growth and development. Rigorous, high-quality randomized trials are needed to evaluate whether improving the periodontal health of pregnant women can reduce the risk of adverse pregnancy outcomes in areas like South Asia, where these outcomes are common and neonatal mortality remains high. This study is a community-based, randomized controlled trial (n=2,280) to evaluate a package of oral health interventions delivered to pregnant women in the first trimester until delivery on the incidence of SVNs in rural Sarlahi District, Nepal. The intervention package will include a daily antiseptic oral rinse and intensive oral hygiene education and instruction. Both intervention and control groups will be provided a manual toothbrush and toothpaste. The investigators will determine intervention effects on incidence of SVNs and individual outcomes of preterm birth, small-for-gestational age, and low birth weight. In a biospecimen sub-study (n=200), the investigators will collect venous blood, gingival crevicular fluid, and plaque in early and late pregnancy to explore relationships between subgingival inflammation, systemic inflammation, and SVN types and other adverse pregnancy outcomes. If efficacious, a low-cost package of oral health interventions - including an antiseptic oral rinse, intensive oral hygiene education and instruction, and provision of a manual toothbrush and toothpaste - could improve maternal and newborn outcomes at this critical time of growth and development.",[176,333,334,335,27],"Low Birth Weight","Small Vulnerable Newborn","Small-for-gestational Age",[337,338,339,340,125,341,342,61,343,344,59,345,346],"Nepal","Oral health","Small Vulnerable Newborns","Preterm birth","Low birth weight","Small-for-gestational age","Antenatal care","Dental health","Antiseptic oral rinse","Oral hygiene","2026-07-08",{"date":349,"type":36},"2026-07-09",{"date":351,"type":21},"2026-10-01",{"date":69,"type":21},{"name":354,"class":43},"Johns Hopkins Bloomberg School of Public Health",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":80,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":72},"100646510","short-implants-in-unitary-implant-supported-rehabilitations-in-the-posterior-maxilla-and-mandible-5-years-of-follow-up-100646510","NCT07688408","Short Implants in Unitary Implant-supported Rehabilitations in the Posterior Maxilla and Mandible: 5 Years of Follow-up","Short Implants (7 and 8 mm) in Unitary Implant-supported Rehabilitations in the Posterior Sector of the Maxilla and Mandible: 5 Years of Follow-up","Inclusion Criteria:\n\n* Individuals (\\> 21 years old), of both sexes, specifically rehabilitated with morse connection implants (Implacil De Bortoli, São Paulo, SP, Brazil) in the posterior region of the jaws for single-sided unsupported restorations, will be included in this study. Individuals will also need to have at least initial radiographic controls (immediately after implant placement) and 12 and 60 months of follow-up after implant placement. Individuals will be included in the population sample, with the following criteria observed: location, implant installation region, implant diameter, and adaptation.\n\nExclusion Criteria:\n\n* Immediate implants will be excluded, individuals with clinical records who, throughout the study, do not have radiographs for evaluation and\u002For radiographs of poor quality that make radiographic measurements impossible; medical records with insufficient data, filled out inappropriately or that indicate doubt about the details of the procedure performed.",{"count":246,"type":21},"Implant-supported rehabilitation of regions with severe bone resorption is a challenge for implant dentists. Structures such as the maxillary sinus and the inferior alveolar canal often make it impossible to use implants of lengths considered standard in the literature. The use of short 7 and 8 mm implants with new macrogeometries and surface treatments, in addition to the application of Morse taper prosthetic connections, has shown results that increasingly encourage their use. However, the longevity of these rehabilitations needs to be constantly evaluated. In this work, unitary implant-supported rehabilitations in the posterior jaws, supported by short (7 and 8 mm) tapered Morse connection implants, will be followed for a period of 5 years. A total of 100 subjects rehabilitated with tapered Morse connection implants, with diameters between 3.5 and 4.5 mm, will be evaluated. Peri-implant bone remodeling, implant stability measured through ISQ and clinical parameters will be evaluated per implant and over the evaluation time. Periapical radiographs will be obtained and digitized, analyzed by software and compared with the initial data. The data obtained will be analyzed, allowing longitudinal evaluations and the success rate of implant restorations supported by short implants.",[93,27],"2026-07-06",{"date":347,"type":36},{"date":368,"type":21},"2026-06-28",{"date":370,"type":21},"2027-02-28",{"name":372,"class":43},"University of Guarulhos",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":267,"maxAge":381,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":388,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":72},"100644677","omega-3-plus-low-dose-aspirin-in-smokers-with-stage-iii-periodontitis-100644677","NCT07673185","Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis","Clinical and Biochemical Evaluation of the Effect of Omega-3 Fatty Acids Plus Low-Dose Aspirin as an Adjunct to Non-Surgical Periodontal Therapy in Smoker Patients With Stage III Periodontitis: A Randomized Double-Blind Placebo-Controlled Clinical Trial","OASP","Inclusion Criteria:\n\n* \\- Male or female smokers aged 30 to 50 years.\n* Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification.\n* Probing pocket depth (PPD) ≥ 5 mm.\n* Clinical attachment loss (CAL) ≥ 5 mm.\n* Presence of at least 20 natural teeth.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* \\- Systemic diseases affecting periodontal health.\n* Pregnancy or lactation.\n* Periodontal treatment within the previous 6 months.\n* Use of antibiotics or anti-inflammatory drugs within the previous 6 months.\n* Allergy or hypersensitivity to omega-3 fatty acids or aspirin.\n* Long-term anticoagulant therapy.\n* History of gastric ulcer or bleeding disorders.\n* Participation in another clinical trial within the previous 3 month","50 Years",{"count":20,"type":21},[24],"This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment",[27,386,387],"Periodontitis (Stage 3)","Smoking Behaviors",[389,390,391],"omega 3","smoker","stage 3",{"date":347,"type":36},{"date":394,"type":36},"2025-01-15",{"date":396,"type":21},"2026-10-30",{"name":398,"class":43},"Al-Azhar University",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":80,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":4},"100646761","longitudinal-evaluation-of-several-modalities-of-treatment-of-peri-implantitis-5-to-23-years-follow-up-100646761","NCT07684001","Longitudinal Evaluation of Several Modalities of Treatment of Peri-implantitis: 5 to 23 Years Follow-up","longitudinal","Inclusion Criteria:The sample included 300 systemically healthy individuals, over 18 years of age, who received some type of treatment (surgical or non-surgical) for peri-implantitis, associated or not with systemic antibiotic therapy. Subjects cannot have undergone periodontal treatment for at least 6 months prior to the start of the study; agree to participate in the study and agree to sign the ICF.\n\n\\-\n\nExclusion Criteria:Individuals who have lost the treated implants after some peri-implant therapy and those who do not accept to sign the ICF will be excluded.\n\n\\-",{"count":407,"type":21},300,"To evaluate the peri-implant conditions of patients undergoing different surgical and non-surgical techniques, associated or not with regenerative therapies after long periods of time (between 5 and 23 years)\n\n3\\. MATERIAL AND METHODS\n\n3.1. Experimental design This retrospective study will evaluate the peri-implant conditions of patients with peri-implantitis treated at the UnG Clinic using various types of treatments. To this end, participants will be selected from the UnG graduate clinic who received some type of treatment (surgical or non-surgical) until 2021. Participants selected for the study must sign the Informed Consent Form (ICF) after verbal and written explanation of the project. Subjects will receive oral hygiene instruction and professional prophylaxis prior to clinical examinations.\n\n3.2. Sample selection This clinical study will be submitted for approval by the Ethics Committee of the University of Guarulhos (CEP-UnG). Subjects (minimum of 50 and maximum of 300) will be recruited and evaluated at the Implantology clinic of Guarulhos University. This sample was obtained based on the power test so that the study presented a power of around 80%, and NCI and bone loss were considered primary variables.\n\n3.3. Inclusion criteria The sample included 300 systemically healthy individuals, over 18 years of age, who received some type of treatment (surgical or non-surgical) for peri-implantitis, associated or not with systemic antibiotic therapy.\n\n3.4. Sample exclusion criteria Individuals who have lost the implants after some peri-implant therapy;' have undergone periodontal treatment for at least 6 months prior to the start of the study.\n\nClinical examinations A single, trained and calibrated examiner will perform all clinical examinations. The examiner will be trained and calibrated before and during the study in order to achieve maximum reproducibility in measurements. The methodology to be used for intra-examiner calibration will be the one recommended by Araujo et al. 2003, in which the standard error of measurement for continuous periodontal clinical parameters is evaluated. For the other clinical variables, the mean level of agreement between the examiners will be determined and considered satisfactory when the value is greater than 90% (Kappa test).\n\nClinical measures\n\nThe following parameters will be recorded at six sites per implant using a periodontal probe North Carolina:\n\n1. Plate index: 0 = absence of plaque; 1 = separate patches of plaque at the cervical margin; 2 = a thin, continuous band of plaque \\[up to 1 mm\\] at the cervical margin of the tooth; 3 = strip of plaque greater than 1 mm, but covering less than 1\u002F3 of the tooth crown; 4 = plaque that covers at least 1\u002F3 but less than 2\u002F3 of the tooth's crown; 5 = plate covering 2\u002F3 or more of the tooth's crown).\n2. Gingival index : 0 = absence of inflammation; 1 = mild inflammation change in color and little change in texture; 2 = moderate inflammation - tempered glasses, redness, edema and hypertrophy; 3 = severe inflammation - marked redness and hyperplasia.\n3. Bleeding on probing: 0 = absence; 1 = presence.\n4. Suppuration: 0 = absence; 1 = presence.\n5. Probing depth: distance (mm) from the peri-implant mucosal margin to the most apical portion of the peri-implant pocket.\n6. Relative attachment level: distance (mm) from the implant shoulder to the most apical portion of the peri-implant pocket.\n7. Keratinized tissue height : vertical distance (mm) measured from the mucogingival line to the peri-implant margin in the center of the buccal face of the implant.\n8. Keratinized tissue thickness 1: measured in the center of the buccal surface of the ridge, at the midpoint between the mucogingival line and the top of the ridge.\n9. Mesial and distal keratinized tissue thickness 2: measured over the ridge (mesial and distal of the implant) when the crown can be removed.\n10. Evaluation of the biotype of peri-implant tissue: thin or thick, according to the visualization of the periodontal probe through the peri-implant tissue.\n\nScrew-retained implant crowns will be removed to observe clinical records, while cemented crowns will not be removed.\n\nRadiographic measurements As a way of evaluating the stability of bone tissue, the interproximal level of the bone crest will be measured by means of periapical radiographs. After the radiographic takes, the radiographs will be scanned and the distance in millimeters from the interproximal bone crest to the base of the implant will be evaluated.",[27,410],"Microbiology",[412,413],"peri-implantitis","periodontal diseases","2026-07-03",{"date":416,"type":36},"2026-07-07",{"date":418,"type":21},"2026-06-29",{"date":420,"type":21},"2027-03-29",{"name":372,"class":43},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":148,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":443,"locationsCount":72},"100644529","effects-of-adjunctive-synbiotic-supplementation-to-non-surgical-periodontal-therapy-in-smokers-with-periodontitis-100644529","NCT07672379","Effects of Adjunctive Synbiotic Supplementation to Non-Surgical Periodontal Therapy in Smokers With Periodontitis","Effects of Adjunctive Synbiotic Supplementation to Non-Surgical Periodontal Therapy on Clinical, Immunological, and Microbiological Parameters in Smokers With Periodontitis","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Diagnosis of generalized Stage III\u002FIV Grade B\u002FC periodontitis\n* Willingness to participate in the study and provide informed consent\n* No periodontal treatment within the last 3 months\n* No use of antibiotics or anti-inflammatory drugs within the last 3 months\n* Not being pregnant or breastfeeding\n* Presence of at least 20 teeth\n* Body mass index (BMI) between 18.5 and 30 kg\u002Fm²\n\nExclusion Criteria:\n\n* Failure to meet voluntary participation requirements\n* Presence of systemic diseases affecting the periodontium or immune response\n* Use of additional dietary supplements\n* Pregnancy or breastfeeding\n* Use of immunosuppressive medications Individuals who may have difficulty complying with the study protocol",{"count":430,"type":21},92,[24],"The aim of this study is to evaluate the effects of adjunctive synbiotic supplementation combined with non-surgical periodontal therapy in smokers with periodontitis. The main questions this study aims to answer are:\n\nDoes adjunctive synbiotic supplementation improve clinical periodontal parameters in smokers with periodontitis? Does adjunctive synbiotic supplementation affect immunological and microbiological parameters associated with periodontal disease?\n\nSystemically healthy smokers and non-smokers diagnosed with generalized Stage III-IV Grade B\u002FC periodontitis will be included in the study. Participants will first be divided into two main groups according to smoking status (smokers and non-smokers). These groups will then be further divided into two subgroups according to the use of synbiotic or placebo capsules. Therefore, the study will consist of four groups in total. The sample size of the study was determined as 92 participants, with 23 participants included in each group.\n\nAll participants will receive non-surgical periodontal therapy (NSPT) at baseline. In addition to NSPT, participants will use either synbiotic or placebo capsules once daily for 90 days.\n\nTo evaluate clinical periodontal, immunological, and microbiological parameters, periodontal measurements will be performed, and saliva and subgingival plaque samples will be collected. In addition, stool samples will be collected from participants to evaluate the effects of synbiotic supplementation on the gastrointestinal microbiota, and microbiota analyses will be performed.\n\nAll samples will be collected again and evaluated at the third month following non-surgical periodontal therapy.",[27],[93,435,436,251],"Non-surgical periodontal treatment","Synbiotic","2026-06-24",{"date":439,"type":36},"2026-06-26",{"date":365,"type":21},{"date":442,"type":21},"2027-10-06",{"name":444,"class":43},"Biruni University",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":80,"sex":18,"minAge":452,"maxAge":171,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":467,"locationsCount":72},"100644467","early-phase-1-comparison-of-the-efficacy-of-conventional-versus-minimally-invasive-non-surgical-periodontal-therapy-in-periodontitis-patients-100644467","NCT07671274","Comparison of the Efficacy of Conventional Versus Minimally Invasive Non-Surgical Periodontal Therapy in Periodontitis Patients","Comparison of the Efficacy of Conventional Versus Minimally Invasive Non-Surgical Periodontal Therapy in Periodontitis Patients (Randomized Controlled Clinical Trial)","Inclusion Criteria:\n\n* • Patients with stage III pericdontitis, according to the American Academy of Periodontology (AAP) and the European Federation of Periodontology (EFP) periodontal classification system .\n\n  * Medically free patients.\n  * Non-smokers\n  * Patients with good oral hygiene.\n\nExclusion Criteria:\n\n* Pregnant or lactating females.\n\n  * Patients with systemic diseases that might affect periodontal health\n  * previous periodontal treatment within 6 months before baseline examination.\n  * prior antibiotic regimen use within 1 month before baseline examination","20 Years",{"count":202,"type":21},[455],"EARLY_PHASE1","the aim of this study is to investigate the clinical outcomes of Minimally Invasive Non-Surgical Therapy(MINST) compared to Conventional non-surgical periodontal therapy (CNST)",[27,458],"Stage III Periodontitis",[460,461,462],"periodontitis","stage III","mechanical debridement",{"date":439,"type":36},{"date":465,"type":36},"2025-08-05",{"date":100,"type":21},{"name":163,"class":43},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":477,"conditions":478,"keywords":486,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":72},"100638972","periodontal-disease-in-rare-renal-disorders-perio-ra-re-100638972","NCT07575347","Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)","Periodontal Inflammation in Rare Renal Disorders - A Cross-Sectional Controlled Observational Study Assessing the Burden and Phenotypes of Periodontal Disease","PERIO-RA-RE","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* At least 10 natural teeth present\n* Belonging to one of the predefined study groups:\n\n  1. Alport syndrome (genetically or clinically confirmed)\n  2. Fabry disease (enzymatically or genetically confirmed)\n  3. Tuberous sclerosis complex (according to established clinical or genetic criteria)\n  4. Systemic lupus erythematosus defined according to the 2019 EULAR\u002FACR or SLICC 2012 classification criteria, with renal involvement defined by at least one of the following: \\[1\\] Biopsy-proven lupus nephritis, \\[2\\] Persistent proteinuria (\\>0.5 g\u002Fday or equivalent), \\[3\\] Active urinary sediment (hematuria and\u002For cellular casts) consistent with lupus nephritis\n  5. Chronic kidney disease (CKD) of non-rare etiology: defined according to KDIGO criteria (eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m² and\u002For markers of kidney damage)\n  6. Individuals without CKD, recruited from clinical or dental care settings as non-CKD controls\n\nExclusion Criteria:\n\n* Periodontal treatment within the last 6 months\n* Antibiotic therapy within the last 4 weeks\n* Pregnancy\n* Conditions precluding periodontal examination\n* Inability to comply with study procedures",{"count":246,"type":21},"This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus erythematosus (SLE), compared with chronic kidney disease (CKD) controls and population controls.\n\nThis is a cross-sectional, case-control observational study. Participants will undergo a single structured evaluation including a full-mouth periodontal examination, a clinical questionnaire, and collection of relevant clinical and nephrological data.\n\nThe primary objective is to compare the prevalence of periodontitis across study groups. Secondary objectives include characterization of periodontal disease severity, prevalence of gingivitis and xerostomia, and identification of disease-specific oral phenotypes.\n\nExploratory analyses will assess associations between periodontal disease and clinical variables such as kidney function, proteinuria, and immunosuppressive exposure.",[27,93,479,480,481,482,483,484,485],"CKD","Chronic Kidney Disease","Alport Syndrome","Fabry Disease","Lupus or SLE","Tuberous Sclerosis Complex (TSC)","Systemic Lupus Erythematosus (SLE)",[27,93,479,487,488,489,484,480],"Rare Kidney Diseases","Alport syndrome","Systemic Lupus Erythematosus",{"date":439,"type":36},{"date":492,"type":36},"2026-05-04",{"date":494,"type":21},"2027-12-31",{"name":496,"class":43},"Stefan Lujinschi",{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":80,"sex":18,"minAge":53,"maxAge":148,"enrollmentInfo":505,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":507,"conditions":508,"keywords":510,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":72},"100641785","salivary-biomarkers-in-periodontal-disease-progression-100641785","NCT07661784","Salivary Biomarkers in Periodontal Disease Progression","Evaluation of Salivary Biomarkers Associated With Bone Remodeling in the Transition From Periodontal Health to Disease","PERIO-BIO","Inclusion Criteria:\n\nAdults aged 18-65 years Systemically healthy individuals Individuals classified as periodontally healthy, gingivitis, or periodontitis according to clinical periodontal examination Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\nPresence of systemic diseases affecting periodontal status (e.g., diabetes mellitus, immunological disorders) Use of antibiotics or anti-inflammatory drugs within the last 3 months History of periodontal treatment within the last 6 months Pregnancy or lactation Smoking (optional ) Any condition that may affect salivary biomarker levels",{"count":506,"type":21},240,"This study aims to evaluate salivary biomarkers associated with bone remodeling during the transition from periodontal health to disease. Periodontal diseases are characterized by chronic inflammation that can lead to connective tissue destruction and alveolar bone loss. Although diagnosis is primarily based on clinical and radiographic findings, these methods may not fully reflect disease activity or progression.\n\nIn this observational study, individuals with periodontal health, gingivitis, and periodontitis will be included. Salivary levels of IL-17, IL-23, IL-6, TGF-β, RANKL, and OPG will be measured using ELISA. The relationship between these biomarkers and periodontal disease stage and grade will be analyzed.\n\nThe results are expected to improve understanding of the biological mechanisms underlying periodontal disease progression and to assess the potential role of salivary biomarkers in early diagnosis and personalized treatment approaches.",[27,509,93],"Gingivitis and Periodontal Diseases",[27,59,93,511,512,513,514,183,515,516,517,518,519],"Salivary Biomarkers","Bone Remodeling","Interleukin-17 (IL-17)","Interleukin-23 (IL-23)","Transforming Growth Factor Beta (TGF-β)","RANKL","Osteoprotegerin (OPG)","ELISA","Non-invasive Diagnosis","2026-06-16",{"date":522,"type":36},"2026-06-22",{"date":524,"type":36},"2025-07-10",{"date":526,"type":21},"2026-08-30",{"name":528,"class":43},"Suleyman Demirel University",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":18,"minAge":536,"maxAge":537,"enrollmentInfo":538,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":540,"conditions":541,"keywords":542,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":72},"100643006","mental-health-and-periodontitis-in-probable-bruxers-100643006","NCT07634250","Mental Health and Periodontitis in Probable Bruxers","Association Between Mental Health Status and Periodontitis Among Probable Bruxers","Inclusion Criteria:\n\n1. Adult periodontitis patients with age group 30-50 years diagnosed with probable bruxism.\n2. Presence of minimum 20 teeth excluding third molars.\n\nExclusion Criteria:\n\n* History of systemic disease such as diabetes or autoimmune disease\n* History of drugs having the potential impact on periodontal status like phenytoin, cyclosporin, calcium-channel blockers or antidepressant drugs.\n* Pregnant or lactating females.\n* Post-menopausal women.\n* Patients diagnosed with temporomandibular disorders- pain and tenderness in the masticatory muscles","30 Months","50 Months",{"count":539,"type":21},110,"The goal of this observational study is to learn how mental health affects periodontal health in people having teeth grinding (bruxism).\n\nThe main questions it aims to answer are:\n\nDoes poor mental health increase the risk of periodontitis in people with teeth grinding? Does stress link teeth grinding and periodontitis?\n\nParticipants are people who likely have teeth grinding(bruxism) and periodontitis\n\nParticipants will:\n\nAnswer questions about their mental health, including stress Get a periodontal health status check\n\nTeeth grinding(Bruxism) can occur due to stress, smoking, alcohol use, and bite problems. Stress may affect muscle activity and lead to teeth grinding. It can also weaken the body's defense and lead to poor oral care. This may worsen periodontal health.",[27],[543,544],"mental health status","probable bruxism","2026-06-03",{"date":547,"type":36},"2026-06-08",{"date":549,"type":21},"2026-06",{"date":551,"type":21},"2026-09",{"name":553,"class":43},"Postgraduate Institute of Dental Sciences Rohtak",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":148,"enrollmentInfo":562,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":577,"leadSponsor":579,"locationsCount":72},"100643347","photodynamic-therapy-as-an-adjunct-in-periodontal-treatment-100643347","NCT07633405","Photodynamic Therapy as an Adjunct in Periodontal Treatment","Clinical Evaluation of Photodynamic Therapy as an Adjunct to Scaling and Root Planing in the Treatment of Periodontal Disease: A Split-Mouth Randomized Controlled Clinical Trial","PDT-PERIO","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosis of Stage I, II, III, or IV periodontitis according to the 2018 World Workshop Classification.\n* Presence of at least two hemiarches with periodontal pockets ≥5 mm suitable for a split-mouth design.\n* Systemically healthy individuals.\n* No periodontal treatment received within the previous 6 months.\n* No use of antibiotics, anti-inflammatory drugs, or antiseptic mouth rinses within the previous 3 months.\n* Ability and willingness to provide written informed consent and attend follow-up visits.\n\nExclusion Criteria:\n\n* Uncontrolled systemic diseases that may affect healing or immune response.\n* Use of antibiotics, corticosteroids, or immunosuppressive medications within the previous 3 months.\n* Active smokers consuming more than 10 cigarettes per day.\n* Pregnant or breastfeeding women.\n* Presence of dental implants, defective restorations, or teeth with Grade III mobility in the selected study sites.\n* Known allergy to toluidine blue O or any component of the photosensitizer.\n* Individuals unable or unwilling to attend the 30-day follow-up visit.",{"count":202,"type":21},[24],"This study aims to evaluate the clinical effectiveness of antimicrobial photodynamic therapy (aPDT) as an adjunct to scaling and root planing (SRP) in the treatment of periodontitis. A split-mouth design will be used, in which one hemiarch receives conventional SRP and the contralateral hemiarch receives SRP combined with aPDT. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), plaque index (PI), and gingival index (GI), will be assessed at baseline and 30 days after treatment. The study seeks to determine whether adjunctive aPDT improves periodontal outcomes compared with conventional non-surgical periodontal therapy alone.",[93,27],[93,27,567,568,569,570,571,572,573],"Antimicrobial Photodynamic Therapy","Photodynamic Therapy","aPDT","SRP","Clinical attachment level","Low level Laser therapy","Gingival Index","2026-06-02",{"date":547,"type":36},{"date":184,"type":21},{"date":578,"type":21},"2026-09-27",{"name":580,"class":43},"Universidad Catolica Santiago de Guayaquil",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":80,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":589,"conditions":590,"keywords":592,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":72},"100640638","oral-health-and-systemic-diseases-survey-of-general-practitioners-100640638","NCT07604493","Oral Health and Systemic Diseases: Survey of General Practitioners","Oral Health and Systemic Diseases: An Investigative Survey of General Practitioners","Inclusion Criteria:\n\n* Licensed General Practitioners currently practicing in Italy\n* Ability to understand and complete the questionnaire in Italian\n* Voluntary agreement to participate after reading study information and providing informed consent\n\nExclusion Criteria:\n\n* Physicians not currently practicing as General Practitioners\n* Incomplete questionnaire responses\n* Duplicate submissions\n* Participants who decline informed consent",{"count":246,"type":21},"This cross-sectional observational study aims to assess the level of knowledge, clinical practices, and professional attitudes of General Practitioners (GPs) regarding oral health and its relationship with major systemic diseases, with particular emphasis on periodontal disease. Data will be collected through an anonymous, self-administered digital questionnaire distributed nationwide to General Practitioners practicing in Italy. The questionnaire will investigate participants' knowledge of oral diseases, awareness of oral-systemic associations, early identification of oral manifestations, educational background, and interdisciplinary collaboration with dental professionals.",[27,591],"Diabete Mellitus",[593,594,460],"smoking","diabetes","2026-05-23",{"date":597,"type":36},"2026-05-28",{"date":599,"type":36},"2026-01-01",{"date":601,"type":21},"2027-01-01",{"name":603,"class":43},"University of Roma La Sapienza",{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":72},"100637477","periodontal-disease-in-patients-with-lynch-syndrome-100637477","NCT07600710","Periodontal Disease in Patients With Lynch Syndrome","Periodontal Disease in Patients With Lynch Syndrome: a Retrospective Observational, Monocentric Case-control Study","SMILy_25","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. All sexes eligible\n3. Established diagnosis of LS performed as part of clinical practice, with a germline pathogenic\u002Flikely pathogenic variant in one of the following genes: MLH1, MSH2, MSH6, PMS2, and EpCAM\n4. LS subjects undergoing surveillance gastrointestinal endoscopy according to clinical practice and international guidelines.\n5. Subjects underwent dental and periodontal examination\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Absence of sufficient periodontal clinical or radiographic data to establish a periodontal diagnosis;\n3. Subjects affected by systemic, autoimmune, chronic inflammatory, neurological, or severe psychiatric disorders, or by any other clinical condition that may interfere with study participation or data interpretation\n4. Subjects with systemic conditions known to strongly affect periodontal status (e.g. uncontrolled diabetes, autoimmune inflammatory diseases, ongoing cancer therapy) were excluded to reduce major confounding factors that could independently alter periodontal outcomes.",{"count":7,"type":21},"The field of human microbiome research has undergone a revolution in its approach toward understanding how microorganisms influence the physiology of their host 1. The influence of the oral microbiota is not confined to this location 2. Periodontitis is a \"chronic inflammatory disease associated with dysbiotic plaque biofilms and characterized by a progressive destruction of the tooth supporting apparatus\"3. Given these observations, the central research question of the present study is to determine the prevalence of periodontitis in patients with Lynch syndrome (LS) compared with reference prevalence estimates from the general population40.",[615,27],"Lynch Syndrome","2026-05-18",{"date":618,"type":36},"2026-05-22",{"date":620,"type":21},"2026-06-01",{"date":622,"type":21},"2026-07-31",{"name":624,"class":43},"Rotundo Roberto",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":22,"phases":634,"briefSummary":635,"conditions":636,"keywords":638,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":235},"100637557","phase-1-a-novel-proline-rich-peptide-hydrogel-for-periodontal-regeneration-in-adult-periodontitis-patients-100637557","NCT07581613","A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration in Adult Periodontitis Patients","A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration: a Multicenter Parallel-arm Randomized Clinical Trial","PERIHEAL","Inclusion criteria\n\n* Adults \\>18 years with periodontitis (Stage III or IV)\n* Systemically healthy (ASA I or II)\n* Non-smokers or smoking \\\u003C10 cigarettes\u002Fday\n* Having undergone steps 1 (risk factor control, oral hygiene improvement including interdental hygiene) and 2 (subgingival instrumentation and biofilm control) of systematic periodontal therapy\n* Indication for step 3 periodontal therapy, i.e., sites with residual\u002Fpersistent pockets (PPD \\>5 mm and BoP or PPD \\>6 mm) around single- or multi-rooted teeth with mobility \\\u003Cgrade II at re-evaluation 8-12 weeks after non-surgical instrumentation (Step 2). Further site-specific criteria include at least one site with a radiographic infrabony defect (2- or 3-walled) with a \\>3 mm intrabony component, not associated with an open furcation, indicated for regenerative surgery\n* Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) ≤20% before surgery\n\nExclusion criteria\n\n* Medical conditions contraindicating surgery\n* Pregnancy or lactation\n* Current use of systemic antibiotics\n* Smoking \\>10 cigarettes\u002Fday\n* FMPS or FMBS \\>20%\n* Mobility grade II or greater\n* Acute oral infections, active endo-perio lesions or active carious lesions on teeth associated with bone defects",{"count":20,"type":21},[152,153],"The goal of this clinical trial is to learn if a novel peptide-rich hydrogel works to achieve periodontal regeneration in adults. It will also learn about the safety of the hydrogel. The main questions it aims to answer are:\n\n* Does the novel peptide hydrogel achieve periodontal regeneration to a similar degree as another currently used therapy (hyaluronic acid)?\n* What medical problems, if any, do participants have when receiving the novel hydrogel treatment? Researchers will compare the novel peptide hydrogel to another commonly used hydrogel (hyaluronic acid) to see if the peptide hydrogel works to treat periodontal bone defects.\n\nParticipants will:\n\n* Receive the novel hydorgel or hyaluronic acid when they undergo periodontal regenerative surgery\n* Visit the clinic at regular intervals for 1 year after the surgery for follow ups",[27,637],"Intrabony Periodontal Defects",[639,640],"periodontal regeneration","hydrogels","2026-05-11",{"date":643,"type":36},"2026-05-14",{"date":645,"type":21},"2026-11-01",{"date":647,"type":21},"2030-06-30",{"name":649,"class":43},"Siddharth Shanbhag",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":657,"enrollmentInfo":658,"targetDuration":4,"studyType":22,"phases":660,"briefSummary":661,"conditions":662,"keywords":663,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":72},"100640966","comparison-between-different-interdental-brushes-in-adults-with-periodontal-disease-100640966","NCT07575997","Comparison Between Different Interdental Brushes in Adults With Periodontal Disease.","A Clinical Study Evaluating the Efficacy of an Interdental Brush Versus Comparators in Adults With Periodontal Disease.","Inclusion Criteria:\n\n* Subject aged between 18 and 80 years included\n* Subject having signed his\u002Fher written informed consent for his\u002Fher participation in the study\n* Subject diagnosed with active generalized periodontal disease (excluding gingivitis)\n* Subject having at least 20 natural teeth (10 teeth on each side (right and left))\n\nNon-inclusion criteria:\n\n* Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his\u002Fher consent in writing and to report required information in a questionnaire\n* For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study\n* Subject having any other oral condition than periodontal disease (ex: dermatologic ulcers), or any orthodontic conditions liable to interfere with the study assessment or considered by the investigator hazardous for the subject or incompatible with study requirements\n* Systemic treatment or topical treatment\u002Fproduct currently taken\u002Fapplied in the mouth liable to interfere with study assessments according to the investigator or planned to be taken\u002Fapplied during the study\n* Subject has received periodontal therapy (scaling, root planing, surgery, etc.) within 2 months before the inclusion\n* Subject who has undergone oral or gum surgery within 2 months before the inclusion, or planned to be performed during the study","80 Years",{"count":659,"type":21},88,[24],"The aim of this exploratory study is to evaluate the efficacy of the tested interdental brush versus comparative interdental brushes in adults with periodontal disease, over a 4-week period.",[27],[27,664],"Interdental Brushes",{"date":666,"type":36},"2026-05-08",{"date":668,"type":36},"2026-04-10",{"date":670,"type":21},"2027-06-30",{"name":672,"class":673},"Pierre Fabre Dermo Cosmetique","INDUSTRY"]